随着癌症病例的不断增加，抗肿瘤药物的使用预计将增加。这将伴随着职业暴露增加，可能会导致工人出现不良健康影响。我们的目标是概述职业暴露于抗肿瘤药物后的基因毒性和表观遗传效应，并评估浓度-效应关系。在四个数据库中搜索有关调查职业暴露于抗肿瘤药物的基因毒性和/或表观遗传效应的论文。从检索到的245篇论文中，有62篇被纳入本次综述。在这个系统性文献综述中，我们证实了医护人员接触抗肿瘤药物可能导致基因毒性损伤。然而，我们观察到对于除医护人员以外的工人的暴露，基因毒性和表观遗传效应的数据缺乏。此外，还发现了关于抗肿瘤药物暴露引起的潜在表观遗传效应以及职业暴露于抗肿瘤药物后内部抗肿瘤药物浓度与基因毒性和表观遗传效应之间的联系的当前知识缺口，为未来的研究提供了第一步。©2023年，作者们在Springer Nature旗下的Springer-Verlag GmbH Germany独家许可下投稿。

With increasing numbers of cancer cases, the use of antineoplastic agents is expected to rise. This will be accompanied by an increase in occupational exposure, which can cause unwanted health effects in workers. Our aim was to give an overview of genotoxic and epigenetic effects after occupational exposure to antineoplastic agents and to assess the concentration-effect relation. Four databases were searched for papers investigating genotoxic and/or epigenetic effects of occupational exposure to antineoplastic agents. Out of the 245 retrieved papers, 62 were included in this review. In this systematic literature review, we confirmed that exposure of healthcare workers to antineoplastic agents can lead to genotoxic damage. However, we observed a lack of data on exposure as well as genotoxic and epigenetic effects in workers other than healthcare workers. Furthermore, gaps in the current knowledge regarding the potential epigenetic effects caused by antineoplastic drug exposure and regarding the link between internal antineoplastic drug concentration and genotoxic and epigenetic effects after occupational exposure to antineoplastic agents were identified, offering a first step for future research.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.